• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine Research >Risk Factors for Early-Onset Peripheral Neuropathy Caused by Vincristine in Patients With a First Administration of R-CHOP or R-CHOP-Like Chemotherapy
【24h】

Risk Factors for Early-Onset Peripheral Neuropathy Caused by Vincristine in Patients With a First Administration of R-CHOP or R-CHOP-Like Chemotherapy

机译：长春新碱在首次给予R-CHOP或R-CHOP样化学疗法的患者中引起早发性周围神经病变的危险因素

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Peripheral neuropathy is a well-known side effect of vincristine (VCR), a microtubule inhibitor used for R-CHOP or R-CHOP-like (namely R-CVP and R-THP-COP) regimens. Previous studies have shown that both the total dose of VCR and the number of treatment cycles are related to the incidence of VCR-induced peripheral neuropathy (VIPN). However, VIPN will also occur during the first treatment cycle regardless of the total dose of VCR or number of treatment cycles (early-onset VIPN). There is little information about early-onset VIPN, and it is difficult to predict. The present study’s goal was to identify risk factors for early-onset VIPN.Methods: We analyzed the case records of patients who had their first administration of an R-CHOP or R-CHOP-like regimen between April 2008 and August 2013 at Tokushima University Hospital in Tokushima, Japan. To identify the risk factors for early-onset VIPN, we performed univariate and multivariate logistic regression analyses.Results: Forty-one patients underwent an R-CHOP or R-CHOP-like regimen for the first time at Tokushima University Hospital between April 2008 and August 2013, and 14 patients had grade 1 or higher early-onset VIPN. A univariate analysis revealed that age, the dose of VCR and the concomitant use of aprepitant appeared to be the risk factors of early-onset VIPN. In our calculation using receiver-operator characteristics curves, the cut-off value for patient age was 65 years and that of the dose of VCR was 1.9 mg. A multivariate analysis revealed that VCR dose ≥ 1.9 mg and the concomitant use of the antiemetic aprepitant were independent risk factors for early-onset VIPN.Conclusions: Our present study showed that the patients who had VCR dose ≥ 1.9 mg and the concomitant use of aprepitant had the risk for early-onset VIPN. This suggests that it is important to use aprepitant in light of the risk of early-onset VIPN and the benefit of aprepitant’s antiemetic effect in R-CHOP and R-CHOP-like regimens.J Clin Med Res. 2014;6(4):252-260doi: http://dx.doi.org/10.14740/jocmr1856w
机译：背景：周围神经病变是长春新碱（VCR）的众所周知的副作用，长春新碱（VCR）是一种用于R-CHOP或R-CHOP样（即R-CVP和R-THP-COP）方案的微管抑制剂。先前的研究表明，VCR的总剂量和治疗周期数均与VCR诱发的周围神经病（VIPN）的发生有关。但是，无论VCR的总剂量或治疗周期数（早期VIPN）如何，VIPN也会在第一个治疗周期内发生。关于早发VIPN的信息很少，因此很难预测。本研究的目的是确定早期VIPN的危险因素。方法：我们分析了德岛大学自2008年4月至2013年8月首次服用R-CHOP或R-CHOP方案的患者的病例记录。日本德岛的医院。为了确定早发性VIPN的危险因素，我们进行了单因素和多因素logistic回归分析。结果：2008年4月至2004年4月间，有41例患者首次在德岛大学医院接受了R-CHOP或R-CHOP样治疗。 2013年8月，有14名患者的1级或更高的早发VIPN。单因素分析显示，年龄，VCR剂量和伴随使用阿瑞吡坦似乎是早期VIPN的危险因素。在我们使用接收者－操作者特征曲线的计算中，患者年龄的临界值为65岁，VCR剂量的临界值为1.9 mg。多因素分析显示，VCR≥1.9 mg并同时使用止吐药是早期发生VIPN的独立危险因素。结论：我们的研究表明，VCR≥1.9 mg并同时使用阿瑞哌地的患者可能会发生VIPN早发的风险。这表明，鉴于R-CHOP和R-CHOP样方案中早产VIPN的风险以及先瑞敏的止吐作用的益处，使用先瑞敏很重要。JClin Med Res。 2014; 6（4）：252-260doi：http://dx.doi.org/10.14740/jocmr1856w

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号